GEM
APGE

Global Endowment Management’s Apogee Therapeutics APGE Stock Holding History

Global Endowment Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,797
Closed -$656K – 76
2026
Q1 		$656K Hold
7,797
– – 0.07% 63
2025
Q4 		$589K Hold
7,797
– – 0.07% 73
2025
Q3 		$310K Hold
7,797
– – 0.04% 118
2025
Q2 		$339K Hold
7,797
– – 0.05% 100
2025
Q1 		$291K Hold
7,797
– – 0.04% 112
2024
Q4 		$353K Hold
7,797
– – 0.05% 130
2024
Q3 		$458K Hold
7,797
– – 0.05% 120
2024
Q2 		$307K Hold
7,797
– – 0.03% 120
2024
Q1 		$518K Buy
+7,797
New +$340K 0.05% 104

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Global Endowment Management's APGE Position: Q2 2026 in Review

Global Endowment Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 7,797 shares — an estimated $656K sold.

Global Endowment Management first reported a position in APGE in Q1 2024 and held it in 9 quarters. The position peaked at $656K in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Global Endowment Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Global Endowment Management sold 7,797 Apogee Therapeutics shares in Q2 2026, an estimated $656K.
  • Global Endowment Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 9 quarters.
  • Global Endowment Management's Apogee Therapeutics position peaked at $656K in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Global Endowment Management's 13F filing for Q2 2026, filed 14 Aug 2026.